Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report
- 15 November 2005
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 85 (2), 134-135
- https://doi.org/10.1007/s00277-005-0028-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpuraAmerican Journal of Hematology, 2005
- Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapyAmerican Journal of Hematology, 2005
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpuraBlood, 2002
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndromeBritish Journal of Haematology, 1997
- Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndromeAnnals of Hematology, 1997
- Anti-Glycoprotein Ib/IX and llb/llla Antibodies in Patients with Antiphospholipid AntibodiesThrombosis and Haemostasis, 1994